Revenue Breakdown
Composition ()
No data
Revenue Streams
Alkermes Plc (ALKS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is VIVITROL, accounting for 30.7% of total sales, equivalent to $121.12M. Other significant revenue streams include LYBALVI and ARISTADA. Understanding this composition is critical for investors evaluating how ALKS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Alkermes Plc maintains a gross margin of 86.91%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 22.60%, while the net margin is 21.00%. These profitability ratios, combined with a Return on Equity (ROE) of 22.35%, provide a clear picture of how effectively ALKS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, ALKS competes directly with industry leaders such as GPCR and CRNX. With a market capitalization of $5.76B, it holds a significant position in the sector. When comparing efficiency, ALKS's gross margin of 86.91% stands against GPCR's N/A and CRNX's 100.00%. Such benchmarking helps identify whether Alkermes Plc is trading at a premium or discount relative to its financial performance.
